BNP Paribas Financial Markets Sells 204,974 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

BNP Paribas Financial Markets cut its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 78.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 55,351 shares of the company's stock after selling 204,974 shares during the quarter. BNP Paribas Financial Markets' holdings in Elanco Animal Health were worth $670,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Jones Financial Companies Lllp grew its position in shares of Elanco Animal Health by 95.6% in the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock valued at $51,000 after purchasing an additional 2,059 shares during the period. SRS Capital Advisors Inc. lifted its position in Elanco Animal Health by 221.2% during the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock valued at $60,000 after buying an additional 3,411 shares in the last quarter. MRP Capital Investments LLC purchased a new stake in Elanco Animal Health during the fourth quarter worth approximately $61,000. Blue Trust Inc. increased its position in shares of Elanco Animal Health by 47.7% in the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock worth $71,000 after acquiring an additional 1,894 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd increased its position in shares of Elanco Animal Health by 3,267.6% in the fourth quarter. Harvest Fund Management Co. Ltd now owns 6,129 shares of the company's stock worth $74,000 after acquiring an additional 5,947 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company's stock.

Elanco Animal Health Price Performance

Shares of NYSE:ELAN traded down $0.01 on Friday, reaching $12.66. 4,743,380 shares of the company traded hands, compared to its average volume of 5,073,930. Elanco Animal Health Incorporated has a fifty-two week low of $8.02 and a fifty-two week high of $18.80. The company's 50 day moving average is $10.34 and its 200-day moving average is $11.45. The stock has a market capitalization of $6.29 billion, a PE ratio of 31.66, a P/E/G ratio of 2.50 and a beta of 1.49. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share for the quarter, topping analysts' consensus estimates of $0.31 by $0.06. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the prior year, the business posted $0.34 earnings per share. Elanco Animal Health's revenue for the quarter was down 1.0% compared to the same quarter last year. As a group, analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ELAN has been the topic of a number of recent research reports. Stifel Nicolaus boosted their price objective on Elanco Animal Health from $15.00 to $16.00 and gave the stock a "buy" rating in a research note on Monday, May 19th. Morgan Stanley lowered their price objective on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 26th. Piper Sandler dropped their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday, March 6th. Barclays lowered their target price on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Finally, UBS Group lowered their target price on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $15.17.

Insider Transactions at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius acquired 10,000 shares of Elanco Animal Health stock in a transaction on Tuesday, March 11th. The stock was bought at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the transaction, the director now owns 111,459 shares of the company's stock, valued at $1,136,881.80. The trade was a 9.86% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 0.89% of the stock is currently owned by company insiders.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.